Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.

abstract：OBJECTIVE:The aim of this study was to evaluate the pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and relevant analytes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and hepatic impairment. METHODS:Patients were enrolled in three independent parallel cohort...

journal_title：Clinical pharmacokinetics

authors： Li C,Agarwal P,Gibiansky E,Jin JY,Dent S,Gonçalves A,Nijem I,Strasak A,Harle-Yge ML,Chernyukhin N,LoRusso P,Girish S

更新日期：2017-09-01 00:00:00

abstract：:The pharmacokinetics of gentamicin were studied after total hip joint arthroplasties in 2 groups of 10 patients. The prosthesis was performed in the first group with 'Palacos R plus gentamicin' (normal viscosity), manufactured by Schering, and in the second group with 'Cerafix genta R' (low viscosity) manufactured by ...

journal_title：Clinical pharmacokinetics

authors： Bunetel L,Segui A,Cormier M,Langlais F

更新日期：1990-10-01 00:00:00

abstract：:Analogues of human insulin have been developed to more closely replicate the physiology of meal-related and basal insulin secretion. Three rapid-acting analogues and two basal analogues are available for clinical use. Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles ...

journal_title：Clinical pharmacokinetics

authors： Roach P

更新日期：2008-01-01 00:00:00

abstract：:Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

journal_title：Clinical pharmacokinetics

authors： Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

更新日期：1986-03-01 00:00:00

abstract：:Obesity is associated with physiological changes that can alter the pharmacokinetic parameters of many drugs. Vancomycin and the aminoglycosides are the only antibacterials that have been extensively investigated in the obese population. The apparent volume of distribution (Vd) and total body clearance of vancomycin a...

journal_title：Clinical pharmacokinetics

authors： Bearden DT,Rodvold KA

更新日期：2000-05-01 00:00:00

abstract：:The treatment of epilepsy in pregnancy is particularly challenging in that the fetal and maternal risks associated with maternal seizures need to be balanced against the potential teratogenic effects of antiepileptic drugs (AEDs). Pregnancy is known to affect the pharmacokinetics of older-generation AEDs. Understandin...

journal_title：Clinical pharmacokinetics

authors： Tomson T,Battino D

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:The aims of this study were to (1) determine whether opportunistically collected data can be used to develop physiologically based pharmacokinetic (PBPK) models in pediatric patients; and (2) characterize age-related maturational changes in drug disposition for the renally eliminated and hepatically metaboliz...

journal_title：Clinical pharmacokinetics

authors： Thompson EJ,Wu H,Maharaj A,Edginton AN,Balevic SJ,Cobbaert M,Cunningham AP,Hornik CP,Cohen-Wolkowiez M

更新日期：2019-07-01 00:00:00

abstract：:The use of salicylates in rheumatic diseases has been established for over 100 years. The more recent recognition of their modification of platelet and endothelial cell function has lead to their use in other areas of medicine. Aspirin (acetylsalicylic acid) is still the most commonly used salicylate. After oral admin...

journal_title：Clinical pharmacokinetics

authors： Needs CJ,Brooks PM

更新日期：1985-03-01 00:00:00

abstract：OBJECTIVE:The objective of this analysis was to simulate the performance of oral triptan formulations with varying absorption characteristics and their impact on the onset and magnitude of the antimigraine effect using a Markov model for migraine attacks. ANALYSIS:Sumatriptan pharmacokinetic data were obtained from cl...

journal_title：Clinical pharmacokinetics

authors： Maas HJ,Spruit MA,Danhof M,Della Pasqua OE

更新日期：2008-01-01 00:00:00

abstract：:This article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P450 (CYP) isoform(s) metabolising a particu...

journal_title：Clinical pharmacokinetics

authors： Bertz RJ,Granneman GR

更新日期：1997-03-01 00:00:00

abstract：BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

journal_title：Clinical pharmacokinetics

authors： Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

更新日期：2005-01-01 00:00:00

abstract：:The pharmacokinetics of cephradine, a cephalosporin with a low degree of protein binding, was studied in 12 women after oral and intravenous administration of the drug during and after pregnancy. Six of the 12 women also received a cephalosporin with a high degree of protein binding, cefazolin, intravenously during an...

journal_title：Clinical pharmacokinetics

authors： Philipson A,Stiernstedt G,Ehrnebo M

更新日期：1987-02-01 00:00:00

abstract：INTRODUCTION:The inhaled corticosteroid (ICS) fluticasone furoate is in development, in combination with the long-acting beta2-agonist vilanterol for the once-daily treatment of asthma and chronic obstructive pulmonary disease and as a monotherapy treatment for asthma. Corticosteroids, including ICSs, have the potentia...

journal_title：Clinical pharmacokinetics

authors： Allen A

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bosentan is a competitive antagonist on endothelin receptor A and B (ETA and ETB), displacing the endogenous binding partner endothelin-1 (ET-1) from its binding sites. After administration of escalating single doses of 10-750 mg as an intravenous (i.v.) infusion, bosentan showed dose-dependen...

journal_title：Clinical pharmacokinetics

authors： Volz AK,Krause A,Haefeli WE,Dingemanse J,Lehr T

更新日期：2017-12-01 00:00:00

abstract：:The pharmacokinetics of metoprolol have been studied in a group of patients with varying degrees of renal impairment and in healthy subjects after administration of 20 mg of metoprolol tartrate intravenously and 50 mg orally in a single dose and during steady-state conditions. There were no significant differences in ...

journal_title：Clinical pharmacokinetics

authors： Jordö L,Attman PO,Aurell M,Johansson L,Johnsson G,Regårdh CG

更新日期：1980-03-01 00:00:00

abstract：:The relation between steady-state plasma ethosuximide level and drug dose was studied in 46 patients. In this population, plasma drug levels were proportional to drug dose, expressed on a body weight basis. Age did not alter this relationship, but plasma levels increased more rapidly, relative to dose, in females than...

journal_title：Clinical pharmacokinetics

authors： Smith GA,McKauge L,Dubetz D,Tyrer JH,Eadie MJ

更新日期：1979-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection. METHODS:A populati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Li H,Zhu L,Bifano M,Eley T,Osawa M,Ueno T,Hughes E,Bertz R,Garimella T,AbuTarif M

更新日期：2017-10-01 00:00:00

abstract：:Renewed interest in vancomycin over the past decade has led to an abundance of data concerning the pharmacokinetics of vancomycin, and its dosage selection and concentration-response relationships. No definitive data exist that correlate vancomycin serum concentrations with clinical outcomes. However, inconsistencies ...

journal_title：Clinical pharmacokinetics

authors： Leader WG,Chandler MH,Castiglia M

更新日期：1995-04-01 00:00:00

abstract：:Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20...

journal_title：Clinical pharmacokinetics

authors： Mahmood I,Sahajwalla C

更新日期：1999-04-01 00:00:00

abstract：:Various pharmacokinetic models, both simple and complex, have been developed to describe the way in which the rate of hepatic elimination of drugs depends on hepatic blood flow, hepatic intrinsic clearance and unbound fraction of drug in blood. A model is necessary because it is not possible to measure the average blo...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,Smallwood RA

更新日期：1990-01-01 00:00:00

abstract：BACKGROUND:Enzyme replacement therapy (ERT) is currently the standard treatment for patients with Gaucher disease type I (GD1), but the pharmacokinetics have hardly been studied. This study aimed to quantify in vivo enzyme activity in peripheral leukocytes from patients receiving long-term treatment with imiglucerase o...

journal_title：Clinical pharmacokinetics

authors： Gras-Colomer E,Martínez-Gómez MA,Moya-Gil A,Fernandez-Zarzoso M,Merino-Sanjuan M,Climente-Martí M

更新日期：2016-09-01 00:00:00

abstract：:Since up to 90% of a theophylline dose is biotransformed, drugs influencing microsomal enzyme systems in the liver may affect the elimination of theophylline. Other integrated mechanisms (e.g. hepatic uptake) may also be altered by concurrent administration of other drugs. Whatever the mechanism, the interaction may b...

journal_title：Clinical pharmacokinetics

authors： Jonkman JH,Upton RA

更新日期：1984-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Iron-rich transfusions and/or a compensatory increase in iron absorption ultimately result in iron loading in patients with β-thalassaemia. Hence, without iron chelation, iron accumulates relentlessly. Deferiprone has been shown to be capable of reducing the iron burden in patients with β-thala...

journal_title：Clinical pharmacokinetics

authors： Limenta LM,Jirasomprasert T,Jittangprasert P,Wilairat P,Yamanont P,Chantharaksri U,Fucharoen S,Morales NP

更新日期：2011-01-01 00:00:00

abstract：:20 routine patients with endogenous depression were investigated in a kinetic and 4 week treatment study. Steady-state plasma nortriptyline concentrations above 200 microgram/L were associated with a highly significant poorer therapeutic outcome. The correlations between the 24, 48 and 72 hour concentrations and stead...

journal_title：Clinical pharmacokinetics

authors： Montgomery SA,McAuley R,Montgomery DB,Braithwaite RA,Dawling S

更新日期：1979-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer. The aim of this phase II, crossover, bioequivalence study was to compare the pharmacokinetics (primary objective) and tolerability (secondary objective) of tegafur-uracil (UFT) given as three daily doses (tid, r...

journal_title：Clinical pharmacokinetics

authors： Etienne-Grimaldi MC,François E,Cardot JM,Renée N,Douillard JY,Gamelin E,Bennouna J,Château Y,Milano G

更新日期：2007-01-01 00:00:00

abstract：:Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate ...

journal_title：Clinical pharmacokinetics

authors： Zandvliet AS,Schellens JH,Beijnen JH,Huitema AD

更新日期：2008-01-01 00:00:00

abstract：:Fluorouracil is used clinically against various solid tumours. Both fluorouracil toxicity and pharmacokinetics vary highly within and between individuals. The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal fluorouracil exposure or dose because of a ...

journal_title：Clinical pharmacokinetics

authors： Ploylearmsaeng SA,Fuhr U,Jetter A

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Numerous population pharmacokinetic (PK) models of tacrolimus in adult transplant recipients have been published to characterize tacrolimus PK and facilitate dose individualization. This study aimed to (1) investigate clinical determinants influencing tacrolimus PK, and (2) identify areas requ...

journal_title：Clinical pharmacokinetics

authors： Kirubakaran R,Stocker SL,Hennig S,Day RO,Carland JE

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

更新日期：2016-12-01 00:00:00

abstract：:Sex-related differences in the disposition of some analgesics, anxiolytics and hypnotics have recently been reported. With certain benzodiazepines, sex has been shown to be a more important determinant of variability in drug disposition than age, while with other benzodiazepines an age-related decline in clearance was...

journal_title：Clinical pharmacokinetics

authors： Wilson K

更新日期：1984-05-01 00:00:00